Atlas Trials

Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC

Clinical trial NCT06153368 · UNKNOWN

Trial details

NCT number
NCT06153368
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer
Start date
2023-12-19
Primary completion
2024-11-27
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.